"目录号: HY-14462
Membrane Transporter/Ion Channel-
NP-118809(39-1B4)是N型钙离子通道阻断剂，IC50为0.11 uM，比对L型钙离子通道的抑制性高。
Calcium Channel
相关产品
Verapamil hydrochloride-Chlorpromazine hydrochloride-Neomycin sulfate-Nifedipine-Acetylcholine chloride-Diltiazem hydrochloride-Mibefradil dihydrochloride-Bay-K-8644 ((R)-(+)-)-Nimodipine-Cilnidipine-Dantrolene sodium hemiheptahydrate-Nicardipine Hydrochloride-Amlodipine besylate-Cromolyn sodium-Levetiracetam-
生物活性
Description
NP-118809(39-1B4) is a potent N-type calcium channel blockers(IC50= 0.11 uM) ; good selectivity over L-type calcium channels.IC50 Value: 0.11 uM (for N-type Calcium channel) [1]Target: N-type calcium channelin vitro: NP-118809, exhibited increased N-type channel blockade (IC50=0.11 uM) and was 111-fold more selective for N-type channels (L-type calcium channel IC50=12.2 uM) [1]. In the N,4-dibenzhydryl-piperazine-1-carboxamide series (21-27), non-substituted derivative (21) showed a similar inhibitory activity for N-type calcium channels (est. IC50=0.15 uM) as that of parent compound, NP-118809 (est. IC50=0.11 uM). 1-[Phenyl(pyridin-4-yl)methyl]piperazine (42), with no substituent on the nitrogen showed good N-type blocking activity (est. IC50=0.06 uM) while the N-methylated analog (43) was an order of magnitude less potent (est. IC50=0.69 uM) [2].in vivo: NP-118809, i.v. at 2 mg/kg or p.o. at 10 mg/kg in rats, showed acceptable absorption (Tmax=2.3 hr) and half-life (2.1 hr) characteristics and a mean oral bioavailability of 30%. Both compounds were widely distributed outside of plasma and/or bound to plasma proteins. Upon i.p. administration of NP-118809 and NP-078585 at 25 mg/kg, both showed analgesic activity in Phase IIA portions of the rat formalin model. A single 1 uM dose application of NP-078585 blocked hERG currents showing its potential for cardiovascular liability [1].
References
[1].Zamponi GW, et al. Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72.
[2].Pajouhesh H, et al. Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1378-83.